OncoMatch/Clinical Trials/NCT03198546
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
Is NCT03198546 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies GPC3 and/or TGFβ targeting CAR-T cells for hepatocellular carcinoma.
Treatment: GPC3 and/or TGFβ targeting CAR-T cells — The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test the anti-cancer function by the GPC3/TGFβ-CAR-T cells in human HCC patients with GPC3 expression. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/TGFβ-CAR-T cell immunotherapy on human will firstly be tested.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: GPC3 overexpression (protein expression)
patients with advanced HCC,which express GPC3 protein
Demographics
Prior therapy
Cannot have received: gene therapy
Had accepted gene therapy before
Lab requirements
Kidney function
adequate kidney function
Liver function
child-pugh-turcotte score <7
Cardiac function
adequate heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03198546 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Does this trial require GPC3?
Yes, GPC3 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify